Alvotech
ALVO
Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas. The company operates a vertically integrated model that covers the biosimilar value chain from cell line development and research to commercial manufacturing. Its portfolio includes monoclonal antibodies and fusion proteins designed to support treatment access across global patient markets. Alvotech SA works through strategic partnerships to extend commercialization and distribution reach across North America, Europe, Asia, and other international markets. Headquartered in Luxembourg, Alvotech SA plays a role in expanding access to biosimilar medicines within the global biopharmaceutical sector.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$492M
▲ +19.7% YoY
Net Income (TTM)
-$180M
▲ +112.0% YoY
Op. Margin
9.66%
▼ -0.9pp YoY
ROIC
2.96%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$334M
▲ +50.2% YoY
Op. Cash Flow (TTM)
-$199M
▲ +68.9% YoY
Net Debt
$1.28B
Cash & Equiv.
$172M
3Y CAGR: +91.9%
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with ALVO
Held by ETFs
ALVO is in 9 US ETFs. The largest of them, with ALVO's weight in each:
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
iShares Biotechnology ETFIBB0.06%of the fund
SPDR S&P Emerging Markets Small Cap ETFEWX0.08%of the fund
Vanguard Emerging Markets Ex-China ETFVEXC0.01%of the fund
iShares Genomics Immunology and Healthcare ETFIDNA0.47%of the fund
ProShares Ultra Nasdaq BiotechnologyBIB0.06%of the fund
Alvotech (ALVO) in four numbers
Questions about Alvotech
Is Alvotech (ALVO) overvalued?
At $4.12, Alvotech's price is 37% below the $6.57 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Alvotech's fair value?
Intrinsiqq's calculator puts Alvotech's fair value at $6.57 a share. It grows revenue per share 20% a year for 5 years, applies an exit P/S of 2.7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.93. Every input can be changed on the Intrinsic Value tab.
Is Alvotech a high-quality business?
Alvotech scores 30 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from company filings. Its best check is revenue growth at 56.0%, and its weakest is return on capital at 3.0%. The Quality tab shows every check against its target.
Does Alvotech (ALVO) pay a dividend?
No. Alvotech (ALVO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ALVO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.